Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of VACCITECH PLC - AMERICAN DEPOSITARY SHARES
No Price
30.04.2026 14:25
Current Prices from VACCITECH PLC - AMERICAN DEPOSITARY SHARES
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
OSLO BORS
NYKD.OL
NOK
30.04.2026 14:25
3,23 NOK
-
Düsseldorf
NTASAN85.DUSB
EUR
30.04.2026 06:12
0,24 EUR
-
Quotrix
NTASAN85.DUSD
EUR
30.04.2026 05:27
0,28 EUR
-
Share Float & Liquidity
Free Float52,33 %
Shares Float170,88 M
Shares Outstanding326,55 M
Company Profile for VACCITECH PLC - AMERICAN DEPOSITARY SHARES Share
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
